Medical University of South Carolina

Institutional Biosafety Committee Meeting Minutes

Meeting Date	Thursday, February 12, 2026
Meeting Time	12:02 PM –1:19 PM
Meeting Type	Teams Meeting
IBC Members Present	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Lisa Steed, Ph.D., (IBC Member) 5. Carlene Brandon, MS. (Local Non-affiliated Member) 6. Natalie Sutkowski, Ph.D. (Member) 7. Ana Zimmerman, Ph.D. (Local Non-affiliated Member) 8. Logan Patterson, Ph.D. (IBC Member) 9. Daniel Eldridge, DVM (IBC Member, Animal Expert)
Quorum	Number of Members Present (Voting): 9 Number of Members Not Present: 2 Late Arrival of Voting Members: 0 Early Departure of Voting Members: 0
Other Individuals in Attendance	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator)
Call to Order	The IBC Chair called the meeting to order at 12:02 PM
Conflicts of Interests	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.
Review and Approval of Previous Meeting Minutes	December 11, 2025 and January 8, 2026 IBC meeting minutes were discussed and approved. December Voting: For: 7; Against: 0; Abstain: 2 January Voting: For: 9, Against: 0, Abstain: 0
Review of Prior Business	Discussed generation of IBC sample protocol for MUSC users.
New IBC Registration and Amendments for Review (repeat for each registration)	

Protocol #	IBC-25-332
PI Name	Jenkins, Russell
Study Title	Exploring novel therapeutic strategies to overcome resistance to cancer immunotherapy.
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes

	☐ RG2 microbes ☐ Biological toxins ☒ Gene modified mouse cells ☒ Gene modified human cells ☐ Other		
rDNA Category	III-D1a, III-D4b, III-F		
Modified microbes or vectors	Lentivirus		
Transgene expression	Cas9, [redacted]		
Highest BSL	BSL2, ABLS2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☒ BSL2 ☒ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
Votes			
For:9	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-361
PI Name	Sprague, Daniel
Study Title	Generation of ARID1A-mutant Cell Lines Using Lentivirus
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☒ Gene modified human cells ☐ Other
rDNA Category	III D1a, III-D4b
Modified microbes or vectors	Lentivirus

Transgene expression	ARID1A, PRKD2, GRIM19/NDUFA13, ZNF793, SEC16A, BNIPL, PPM1J, CLASRP, ARPP19, TACSTD2, FAM221A, MPP7, CYB5R3, MSRB2, ZDHHC2, RABGGTA, SGPL1, ARHGAP30, SLC39A9, TALDO1, PA2G4, eGFP, PNPLA4		
Highest BSL	BSL2, ABSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:9	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-359
PI Name	Schmidt, Christin
Study Title	Schmidt C. Lab
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☒ Gene modified human cells ☐ Other:
rDNA Category	III-D1a, III-D4b
Modified microbes or vectors	Lentivirus
Transgene expression	MYCN, GFP, PRDM6, CMYC, ZMYM3, TBR2, BARHL1, MCHERRY, HES6, HEY1, HMGB1, HMGB2, INSM1, NFIA, NFIB, OTX2, PAX6, LMX1A, TBR2, Cas9, ZEB1
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending

Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:9	Against:0	Abstained:0	Recused:0

Protocol #	IBC-26-15
PI Name	Yu, Hong
Study Title	Modulating immune signaling pathways in [redacted]
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☒ Gene modified mouse cells ☐ Gene modified human cells ☐ Other:
rDNA Category	III-D1a
Modified microbes or vectors	Lentiviral vector, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis (microbes not genetically modified)
Transgene expression	CD38
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:9	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-228
PI Name	Jiang, Wei
Study Title	Investigating the mechanism of neuropathogenesis of Alzheimer's Disease in response to oral pathobionts
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☒ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other:
rDNA Category	N/A
Modified microbes or vectors	Streptococcus infantis, Streptococcus pneumoniae, Porphyromonas gingivalis, Prevotella salivae, Streptococcus vestibularis, Saccharomyces cerevisiae (microbes not genetically modified)
Transgene expression	N/A
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☐ Yes ☒ Microbes will be shed and may impact other studies in the room if DLAR procedures are not followed

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Woodward
Votes			
For:9	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-340		
PI Name	Voelkel-Johnson, Christina		
Study Title	Voelkel-Johnson IBC		
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☒ Gene modified human cells ☐ Other:		
rDNA Category	III-D1a, III-D4b		
Modified microbes or vectors	Adenoviral and lentiviral vectors		
Transgene expression	ASAH1, CDKN1A, GFP, RFP, luciferase, FUCCI, p53		
Highest BSL	BSL2, ABSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:1

Meeting Adjournment	The IBC Chair called for the meeting to be adjourned at 1:19 PM